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Neutrophil Activation by 
Antibody Receptors
Carlos Rosales and Eileen Uribe-Querol
Abstract
Neutrophils, the most abundant leukocytes in blood, are relevant cells of both 
the innate and the adaptive immune system. Immunoglobulin (Ig) G antibody 
molecules are crucial activators of neutrophils. IgGs identify many types of 
pathogens via their two Fab portions and are in turn detected through their Fc 
portion by specific Fcγ receptors (FcγRs) on the membrane of neutrophils. Thus, 
antibodies bring the specificity of the adaptive immune response to the potent 
antimicrobial and inflammatory functions of neutrophils. Two types of FcγRs 
with several polymorphic variants exist on the human neutrophil. These recep-
tors are considered to be redundant in inducing cell responses. Yet, new evidence 
presented in recent years on how the particular IgG subclass and the glycosylation 
pattern of the antibody modulate the IgG–FcγR interaction has suggested that a 
particular effector function may in fact be activated in response to a specific type 
of FcγR. In this chapter, we describe the main types of FcγRs on neutrophils and 
our current view on how particular FcγRs activate various signaling pathways 
to promote unique effector cell functions, including phagocytosis, activation of 
integrins, nuclear factor activation, and formation of neutrophil extracellular 
traps (NETs).
Keywords: neutrophil, phagocytosis, degranulation, NETs, antibody, Fc receptors, 
integrins, NF-κB
1. Introduction
Neutrophils are the most abundant cell type in human blood. They are 
produced in the bone marrow and then released into the circulation. At sites of 
infection or inflammation, neutrophils migrate to tissues, where they complete 
their functions. Finally, neutrophils die by apoptosis and are eliminated by 
macrophages. Neutrophils are an essential part of the innate immune system [1], 
with significant antimicrobial functions, including phagocytosis, degranula-
tion, and the formation of neutrophil extracellular traps (NETs). These antimi-
crobial functions were believed to be the only goal of neutrophils. However, it 
has recently become clear that neutrophils display many functional responses 
that go beyond the simple killing of microorganisms. Neutrophils produce cyto-
kines [2] and other inflammatory factors [3] that regulate the whole immune 
system [4, 5]. Consequently, neutrophils are also key effector cells of the adap-
tive immune system.
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Immunoglobulin (Ig) G antibody molecules are an essential part of the adap-
tive immune system. IgGs recognize antigens via their two Fab portions and 
are in turn linked through their Fc portion to specific Fcγ receptors (FcγRs) on 
the membrane of leukocytes [6, 7]. In this way, antibodies function as a bridge 
between the specific adaptive immune response and the potent innate immune 
functions of leukocytes. In the human neutrophil, two types of FcγR exist. Thus, 
antibodies are important activators of neutrophils. The Fcγ receptors on the neu-
trophil are considered to be redundant in inducing cell responses [8, 9]. However, 
recent findings on how a particular IgG subclass and the glycosylation pattern of 
the antibody regulate the IgG–FcγR interaction suggest that a particular effector 
function may in fact be activated in response to a specific type of FcγR. It is the 
purpose of this chapter to describe the FcγRs on human neutrophils and present 
our current view of how particular FcγRs activate various signaling pathways to 
promote unique effector cell functions.
2. Neutrophils
Neutrophils are the most abundant leukocytes in blood and because they are 
the first cells to appear at sites of inflammation and infection; they are regarded as 
the first line of defense of the innate immune system [10]. Neutrophils can rapidly 
move from the blood into affected sites through a process known as the leukocyte 
adhesion cascade. Once in the tissues, they perform important antimicrobial func-
tions, including phagocytosis, degranulation, and formation of neutrophil extracel-
lular traps (NETs) [11, 12].
2.1 Leukocyte adhesion cascade
Neutrophils leave the blood circulation at sites of infection or inflamma-
tion by binding to the endothelial cells and then transmigrating into the tissues 
[13]. This process known, as the leukocyte adhesion cascade (Figure 1), begins 
with the activation of endothelial cells at the affected site. Activated endothelial 
cells upregulate the expression of adhesion receptors such as E- and P-selectins. 
Neutrophils bind to these selectins via glycoprotein ligands on their membrane. As 
a consequence, neutrophils can then roll on endothelial cells. Next, neutrophils get 
activated by chemokines, which induce a high affinity state on integrins, another 
group of adhesion receptors. Binding of integrins with their corresponding ligands, 
such as intercellular adhesion molecule-1 (ICAM-1) and ICAM-2 on endothelial 
cells, results in slower neutrophil rolling and then firm adhesion that makes neu-
trophils stop. Finally, neutrophils transmigrate the endothelium into the tissues. 
Engagement of endothelial-cell adhesion molecules seems to provoke the opening 
of endothelial-cell contacts by redistributing junctional molecules in a way that 
promotes transmigration of neutrophils. Molecules that do not help neutrophil 
migration, such as vascular endothelial cadherin (VE-cadherin), are moved away 
from junctional regions. Other endothelial junctional molecules for which neutro-
phils express ligands concentrate on the endothelial cell luminal surface creating an 
adhesive environment for the neutrophil. Platelet/endothelial-cell adhesion mol-
ecule 1 (PECAM1) and CD99 support homophilic interactions between endothelial 
cells and neutrophils. While, junctional adhesion molecule (JAM)-1 and JAM-2 
on the endothelial cell bind to the β1 integrin VLA4, and the β2 integrins LFA-1 
and Mac-1 on the neutrophil, respectively. The endothelial cell-selective adhesion 
molecule (ESAM) is also involved in transmigration by binding to an unknown 
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ligand on neutrophils [12, 14]. Once neutrophils move into tissues, they follow 
chemoattractant gradients to reach affected sites using now adhesion of β1 integ-
rins to proteins of the extracellular matrix, such as collagen and fibronectin [15] 
(Figure 1). Important chemoattractants for neutrophils are activated complement 
components, such as the anaphylatoxin C5a, bacterial components, such as formyl-
methionyl-leucyl-phenylalanine (fMLF) and cytokines, such as interleukin (IL) 8.
2.2 Antimicrobial mechanisms of neutrophils
Neutrophils recruited from the circulation into infected tissues can eliminate 
microorganisms by phagocytosis, by releasing antimicrobial substances or by form-
ing NETs [11, 12] (Figure 2).
2.2.1 Phagocytosis
Phagocytosis is the process by which particles larger than 5 μm get internalized 
by the cell into a vacuole called the phagosome. Neutrophils recognize pathogens 
directly through pattern-recognition receptors (PAMPs), or indirectly through 
opsonin receptors. Opsonins are host proteins, such as antibody molecules or 
complement components, that bind to microorganisms and facilitate their detection 
and destruction by leukocytes [16, 17]. After internalization, the nascent phago-
some matures by fusing with lysosomes [18]. During maturation, antimicrobial 
Figure 1. 
Leukocyte adhesion cascade. Neutrophils, also known as polymorphonuclear (PMN) cells, move to sites of 
inflammation via a leukocyte adhesion cascade that includes activation of endothelial cells with upregulation 
of E- and P-selectins. Neutrophils bind to these selectins via glycoprotein ligands, such as P-selectin glycoprotein 
ligand-1 (PSGL-1), and begin rolling on endothelial cells. Next, neutrophils get stimulated by chemokines and 
activate their β2 integrins, which bind to their corresponding ligands, such as intercellular adhesion molecule-1 
(ICAM-1). Integrin binding induces firm adhesion and transmigration of neutrophils into tissues. Once in 
tissues, neutrophils move following chemoattractant gradients to reach affected sites using now adhesion of β1 
integrins to proteins of the extracellular matrix, such as collagen and fibronectin. Antibodies (IgG) bind to 
microorganisms (bacteria) and are in turn recognized by Fcγ receptors (FcγR) on the membrane of neutrophils.
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molecules are delivered into the phagosomal lumen, and the vesicle is transformed 
into a phagolysosome [19]. In the phagolysosome, reactive oxygen species (ROS) are 
produced by the NADPH oxidase on the phagosomal membrane, and the pH inside 
drops to 4.5–5. Also, hydrogen peroxide (H2O2) is converted to hypochlorous acid 
(HOCl) in a reaction catalyzed by myeloperoxidase (MPO) [20]. Together, these 
actions form a toxic environment for the microorganism.
2.2.2 Degranulation
During neutrophil formation in the bone marrow, immature neutrophils synthesize 
proteins that are sorted into different granules [10]. Granules are classified into three 
different types based on their content. Azurophilic granules contain mainly myeloper-
oxidase, elastase, and cathepsin G. Specific granules contain mainly collagenase, lac-
toferrin, and lysozyme. Gelatinase granules contain mainly gelatinase, lysozyme, and 
cytochrome b558 [21]. Neutrophils also form secretory vesicles at the last step of their 
differentiation. These secretory vesicles contain several important receptors on their 
membrane, including complement receptors (CR1), Fc receptors (CD16), lipopolysac-
charide (LPS) receptors (CD-14), and fMLF receptors. Granule heterogeneity is due 
to the controlled expression of the granule protein genes [22]. Mature neutrophils are 
released into the circulation and when they reach sites of infection, neutrophils can 
degranulate in order to deliver their antimicrobial proteins. Secretory vesicles present 
the greatest predisposition for extracellular release, followed by gelatinase granules, 
specific granules, and azurophil granules [23]. The hierarchical mobilization of 
neutrophil granules and secretory vesicles depend on intracellular Ca2+-level [24].
2.2.3 Neutrophil extracellular traps (NETs)
When neutrophils cannot ingest large microorganisms, they can display another 
antimicrobial strategy [25]. Neutrophils can release long chromatin fibers that are 
decorated with proteins from their granules. These fibers can trap microorganisms, 
and therefore, they have been called neutrophil extracellular traps (NETs) [26]. The 
process of NETs formation is called NETosis [27]. NETosis has been described as a 
special form of programmed cell death. The complete mechanisms of NETs forma-
tion are still unknown; it seems that NETosis requires NADPH oxidase activation, 
reactive oxygen species (ROS) production, myeloperoxidase (MPO), and neutro-
phil elastase (NE) release [28, 29] (Figure 2).
Figure 2. 
Antimicrobial mechanisms of neutrophils. Neutrophils can destroy microbial pathogens, such as bacteria 
by (a) degranulation, (b) phagocytosis, and (c) NETosis. During degranulation, antimicrobial proteins are 
released outside the neutrophil. In phagocytosis, the pathogen is ingested in a vacuole named phagosome, which 
then fuses to lysosomes and becomes a phagolysosome, where the pathogen is destroyed. During NETosis, DNA 
fibers decorated with histones and granular proteins, such as elastase and myeloperoxidase are released in 
structures known as neutrophil extracellular traps (NETs).
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3. Fcγ receptors
Antibodies produced by the adaptive immune response are mainly of the IgG 
class. These antibodies present higher affinity and greater specificity for their 
particular antigen. Thus, IgG antibodies are key for controlling infections from all 
types of pathogens, including viruses, bacteria, fungi, and protozoa [30]. However, 
IgG molecules do not directly damage the microorganisms they recognize. It is in 
fact, the cells of the innate immune system, which are responsible for the anti-
microbial functions of these antibodies. Although, some antibodies can activate 
complement, which is then deposited on microorganisms to promote phagocytosis 
via complement receptors [17, 31], or to induce bacterial lysis via the formation of 
the membrane attack complex [32], most IgG antibodies bind to specific receptors 
on the membrane of leukocytes [7, 8]. These receptors recognize the fragment crys-
tallizable (Fc) portion of IgG molecules and are therefore known as Fcγ receptors 
(FcγR). Cross-linking of FcγR on the surface of cells activates several antimicrobial 
functions [6].
3.1 Human Fcγ receptors
Human Fcγ receptors comprise a family of glycoproteins expressed on the mem-
brane of immune cells [7, 8]. These receptors can bind to the various IgG subclasses 
with different affinities [7], and induce different cellular responses [6]. FcγR can be 
classified as activating receptors (FcγRI/CD64, FcγRIIa/CD32a, FcγRIIIa/CD16a, 
and FcγRIIIb/CD16b), and one inhibitory receptor (FcγRIIb/CD32b) [7, 9, 33, 34] 
(Figure 3).
FcγRI is a high affinity receptor, having three Ig-like extracellular domains. It 
binds mainly monomeric IgG [9]. In contrast, FcγRII and FcγRIII are low-affinity 
receptors, having two Ig-like extracellular domains. They bind only multimeric 
immune complexes [9, 35]. FcγRI is associated with a dimer of the common Fc 
receptor γ chain, which contains an immunoreceptor tyrosine-based activation 
motif (ITAM) sequence (Figure 3). The ITAM sequence is important for receptor 
signaling [36].
FcγRIIa contains its own ITAM within its cytoplasmic tail. In contrast, the 
inhibitory receptor FcγRIIb contains an immunoreceptor tyrosine-based inhibition 
Figure 3. 
Human Fcγ receptors. Schematic illustration of human receptors for IgG. Fcγ receptors are shown relative 
to the cell membrane (brown line). The IgG-binding chain (α) is expressed together with their respective γ2 
signaling subunits. FcγRI is a high affinity receptor, having three Ig-like extracellular domains. FcγRII and 
FcγRIII are low-affinity receptors, having two Ig-like extracellular domains. FcγRIIIb is expressed exclusively 
on neutrophils, and it is a glycosylphosphatidylinositol (GPI)-linked receptor missing a cytoplasmic tail. ITAM, 
immunoreceptor tyrosine-based activation motif with consensus sequence YxxI/Lx (6–12)YxxI/L [36] (green 
oval); ITIM, immunoreceptor tyrosine-based inhibitory motif with the consensus sequence I/V/L/SxYxxL/V 
[39] (red oval).
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motif (ITIM) within its cytoplasmic tail (Figure 3). The FcγRIIb negatively 
regulates various cell functions including antibody production by the B cell [37], 
proliferation, degranulation, and phagocytosis in other leukocytes when it is cross-
linked with activating FcγRs [38, 39]. Most leukocytes express both activating and 
inhibitory FcγRs, hence simultaneous cross-linking establishes a threshold for cell 
activation [40] that maintains a balanced immune response [41, 42].
FcγRIII has two isoforms: FcγRIIIa is a receptor with a transmembrane domain 
and a cytoplasmic tail, associated with an ITAM-containing homodimer of Fc 
receptor γ chains (Figure 3). It is expressed mainly on macrophages, natural killer 
(NK) cells, and dendritic cells [7, 8]. In contrast, FcγRIIIb is expressed exclusively 
on neutrophils and it is a glycosylphosphatidylinositol (GPI)-linked receptor 
missing a cytoplasmic tail. Also, no other subunits are known to associate with it 
(Figure 3). It is important to mention that human FcγRIIa and FcγRIIIb are exclu-
sive receptors that are not found in other species [33, 43].
4. IgG binding to Fcγ receptors
As mentioned before, there is one high-affinity Fcγ receptor, FcγRI (CD64), and 
two groups of low-affinity Fcγ receptors, FcγRII and FcγRIII (Figure 3). This causes 
that a single IgG molecule cannot bind to most Fcγ receptors. However, when IgG 
molecules form antigen-antibody (immune) complexes, they can have many low 
affinity interactions with Fcγ receptors. Thus, only immune complexes are able to 
induce the cross-linking of FcγR required for the activation of various antibody-
mediated cell functions. It is clear then that depending on the nature of the immune 
complex, the interaction with various FcγR will change. Several factors have been 
identified as having an important influence on the affinity of antibody molecules 
for particular FcγRs. These factors include the type of IgG subclass [7, 44], the IgG 
glycosylation pattern [45, 46], and receptor polymorphisms.
4.1 The type of IgG subclass
There are four subclasses of IgG (IgG1, IgG2a, IgG2b, and IgG3 in mice; and 
IgG1, IgG2, IgG3, and IgG4 in humans) [47]. This leads to the formation of differ-
ent types of immune complexes. Several in vivo studies have indeed suggested that 
different IgG subclasses can activate particular cell responses. For example, in mice, 
IgG2b was better than IgG1 at eliminating B cell [48] and T cell lymphomas [49]. 
Also, antierythrocyte antibodies of IgG2a and IgG2b subclasses were better than 
antibodies of IgG1 and IgG3 subclasses in mediating phagocytosis of opsonized 
erythrocytes [50]. In humans, it was shown that most FcγRs bind primarily IgG1 
and IgG3 over the other subclasses of IgG [6, 7]. Together, these reports confirm 
that different IgG subclasses mediate different cellular responses in vivo, and 
suggest that different cellular activities result from cross-linking different FcγRs. 
However, the mechanism used to generate this IgG-FcγR selectivity is not com-
pletely understood. Accordingly, a great interest exists for determining which type 
of IgG binds to which FcγR and what particular receptor is involved in mediating a 
certain cellular function.
Obviously, this selectivity depends mainly on the affinities of different IgG 
subclasses to particular Fcγ receptors. For this reason, detailed studies to measure the 
affinities of IgG subclasses to the various Fcγ receptors have been conducted both for 
mice FcγRs [51] and for all human FcγRs [35]. Through these studies, it was found 
that IgG1 and IgG3 bind to all FcγR. IgG2 binds mainly to FcγRIIa (H131 isoform), 
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and FcγRIIIa (V158 isoform), but not to FcγRIIIb [35]. IgG4 binds to many FcγRs [35]. 
Thus, it is clear that different IgG subclasses engage different Fcγ receptors depend-
ing on the relative affinity of these receptors for a particular IgG class [33].
4.2 The IgG glycosylation pattern
All IgG molecules are glycoproteins with an N-glycosylated carbohydrate side 
chain that is important for antibody function [52]. Deletion of this carbohydrate 
(sugar) side chain results in poor binding to FcγRs [53]. The N-glycans are heteroge-
neous in their sugar composition and are attached to asparagine 297 (Asp297) in the 
Fc portion of the IgG [54]. The carbohydrate side chain may contain sugar residues 
such as galactose, fucose, and sialic acid in straight or branching patterns [46], and 
the differences in the glycosylation pattern seem to regulate IgG activity [55].
Many IgG antibodies present a fucose residue linked to an N-acetylglucosamine 
residue [56]. When this residue is removed, IgG molecules present an increased 
affinity to the FcγRIIIa [57], and also an increase in antibody-dependent cell 
cytotoxicity (ADCC) activity against various tumor cells [51, 57, 58]. Based on these 
findings, recombinant IgG antibodies with low fucose levels have been produced in 
order to increase their ADCC activity. Several of these antibodies are now in clinical 
trials to test their therapeutic potential [59].
Many IgG antibodies also present a carbohydrate side chain that terminates with 
sialic acid residues [60]. Contrary to antibodies without fucose, terminal sialic acid 
usually correlates with low affinity for FcγRs and also with lower ADCC activity 
[61, 62]. Interestingly, these sialic acid-rich antibodies seem to preferentially bind 
other receptors different from FcγRs. The receptor dendritic cell specific ICAM-3 
grabbing nonintegrin (DC-SIGN) was identified as a receptor for sialic acid-rich 
IgG [63]. Therefore, terminal sialic acid can modify IgG activity by promoting less 
binding to FcγRs and more binding to other receptors [45].
4.3 Polymorphisms of receptors
Another factor influencing the affinity of antibody molecules is the existence 
of several polymorphisms for the unique FcγRIIa and FcγRIIIb present on human 
neutrophils [64]. There are two isoforms for FcγRIIa with different amino acids at 
position 131. These are identified as low-responder (H131) and high-responder (R131) 
[65]. Similarly, for FcγRIIIb two isoforms exist differing at four positions, NA1 (R36 
N65 D82 V106) and NA2 (S36 S65 N82 I106) [66], and with different glycosylation 
patterns [67]. In addition, another FcγRIIIb isoform named SH is generated by 
a point mutation (A78D) in the NA2 allele [68]. These multiple FcγR isoforms 
display diverse binding affinity for different IgG classes [35], creating variable cell 
responses to different antibodies.
5. Fcγ receptor signaling
The human neutrophil expresses two unique activating Fc receptors: FcγRIIa 
and FcγRIIIb. FcγRIIa is a receptor containing ITAM sequences [36, 69], and it 
signals similarly to other typical immunoreceptors, such as the antigen receptor of 
T lymphocytes (TCR) and the antigen receptor of B lymphocytes (BCR) [70]. The 
initial signaling steps for all immunoreceptors are alike and involve first cross-
linking of the receptors on the membrane of the cell, followed by the activation of 
Src family tyrosine kinases (Figure 4). These kinases lead to activation of spleen 
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tyrosine kinase (Syk), which in turn phosphorylates tyrosines within the ITAM 
sequence. Phosphorylated ITAM then becomes a binding site for Syk. After bind-
ing to the receptor, Syk phosphorylates multiple substrates leading to different cell 
responses [6, 31, 71] (Figure 4). Syk can phosphorylate and activate phospholipase 
Cγ (PLCγ), which in turn generates diacylglycerol (DAG) and inositol triphosphate 
(IP3). DAG also activates protein kinase C (PKC), an important serine/threonine 
kinase that can lead to the activation of MAP kinases extracellular signal-regulated 
kinase (ERK) and p38 (Figure 4). IP3 induces release of intracellular calcium from 
the endoplasmic reticulum. Calcium regulates several proteins such as calmodulin 
and calcineurin. Syk can also induce activation of phosphatidylinositol-3 kinase 
(PI3K), which produces phosphatidylinositol 3,4,5-trisphosphate (PIP3). This 
phospholipid is relevant to the activation of small GTPases, such as Rho and Rac, 
which are involved in cytoskeleton remodeling for phagocytosis. Rac also leads 
to activation of the MAPK/ERK kinase (MEK)—ERK pathway, and to activation 
of c-Jun N-terminal kinases (JNK). These kinases are important for activation of 
nuclear factors, such as Elk-1, AP-1, and nuclear factor of activated T cells (NFAT) 
(Figure 4). These nuclear factors induce the expression of cytokines important 
for inflammation and immune regulation, such as IL-2, IL-6, IL-8, IL-10, tumor 
necrosis factor α (TNF-α), and IFN-γ [72–74] (Figure 4).
Figure 4. 
Signaling transduction pathway of the neutrophil FcγRIIa. Engagement of activating FcγRIIa by IgG-
antigen immune complexes induces receptor cross-linking and phosphorylation of tyrosine residues in the 
immunoreceptor tyrosine-based activation motif domains (green oval) by Src family kinases. Phosphorylated 
tyrosines then become docking sites for Syk, which in turn phosphorylates multiple substrates leading to 
different signaling pathways that ultimately activate various cell responses. See text for details. P represents a 
phosphate group; Syk, spleen tyrosine kinase; PI3K, phosphatidylinositol-3 kinase; PIP2, phosphatidylinositol 
4,5-bisphosphate; PIP3, phosphatidylinositol 3,4,5-trisphosphate; JNK, c-Jun N-terminal kinase; NFAT, 
nuclear factor of activated T cells; PLCγ, phospholipase Cγ; DAG, diacylglycerol; IP3, inositol triphosphate; 
IP3R, receptor for IP3; ER, endoplasmic reticulum; PKC, protein kinase C; MEK, MAPK/ERK kinase; ERK, 
extracellular signal-regulated kinase; p38, p38 MAP kinase; AP-1, activator protein 1; Elk-1, Ets LiKe gene1 
(ETS) transcription factor; IL-2, interleukin-2; IL-6, interleukin-6; TNF-α, tumor necrosis factor α; and 
IFN-γ, interferon-γ.
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In contrast, the human FcγRIIIb is a GPI-linked receptor that lacks an intracel-
lular portion. Thus, it is not clear how it can connect to intracellular signaling 
molecules. However, there is no doubt that FcγRIIIb is an activating receptor 
inducing several neutrophil responses such as increase in calcium concentra-
tion [75], activation of the respiratory burst [76], activation of integrins [77], 
and induction of NETosis [78, 79]. Despite, the initial signaling mechanism for 
FcγRIIIb remains unknown, the signaling pathway for this receptor engages Syk 
and then transforming growth factor-β-activated kinase 1 (TAK1), as well as the 
MEK/ERK cascade [80] (Figure 5). One possibility to connect FcγRIIIb with Syk 
is that the receptor could link with signaling molecules such as Src family tyrosine 
kinases on the plane of the cell membrane. Because GPI-linked proteins, like 
the FcγRIIIb, concentrate in lipid rafts on the cell membrane together with Src 
kinases [81, 82], we can imagine that after cross-linking FcγRIIIb, it associates 
somehow with these kinases and activates Syk. A possible connection is the bind-
ing of the receptor, within the lipid rafts, to a putative ITAM-containing molecule 
[83]. Many steps are still unknown and future research will help in completely 
elucidate this signaling pathway.
6. Each FcγR leads to unique cellular responses
The signaling pathways activated by immune complexes binding to Fcγ recep-
tors stimulate different neutrophil responses including phagocytosis, respiratory 
burst, cytokine and chemokine production, and antibody-dependent cellular cyto-
toxicity (ADCC) [7, 8, 33]. However, our understanding of what particular function 
is activated in a cell responding to an individual type of FcγR is still very limited. 
This lack of knowledge is due, in part, to the fact that each cell expresses several 
types of FcγRs and all receptors can bind to more than one type of IgG. Thus, it is 
not clear whether each receptor leads to a particular response or the average signal-
ing from various receptors activates a predetermined cell response. Traditionally, it 
Figure 5. 
Signaling transduction pathway of the neutrophil FcγRIIIb. Cross-linking of the human FcγRIIIb by IgG-
antigen immune complexes induces activation of spleen tyrosine kinase (Syk) by a mechanism not yet described. 
Syk then activates transforming growth factor-β-activated kinase 1 (TAK1). TAK1 is in turn required for 
activation of ERK kinase (MEK) and extracellular signal regulated kinase (ERK). Activated ERK signals to 
the nucleus and contributes to activation of NADPH oxidase, which together lead to formation of neutrophil 
extracellular traps (NETs).
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has been thought that each cell is set to activate a particular cell function after FcγR 
cross-linking. More recently, however, another interpretation has been considered: 
each FcγR activates a particular signaling pathway leading to a unique cell response. 
In the traditional view, each cell is already programmed to perform a particular cell 
function after FcγR cross-linking, independently of the receptor used. This idea is 
not really supported by experimental evidence. As indicated above, different IgG 
subclasses bind particular Fcγ receptors with different affinity, leading to unique 
cell functions in vivo [42]. In the most recent view, each FcγR activates a distinctive 
signaling pathway leading to an individual cell function. This view is supported by 
recent reports, where individual FcγRs on human neutrophils initiate particular cell 
responses [77, 78, 84–86].
The idea that particular Fcγ receptors could activate unique cell functions 
was initially published more than 20 years ago. It was found that the neutrophil 
FcγRIIIb induced actin polymerization in a Ca2+-dependent manner, while 
FcγRIIa did not [87]. This initial report was not followed by similar reports and 
the idea of one receptor one response was forgotten. However, with time, other 
reports have provided new evidence that supports this idea. Some years later, 
it was reported that FcγRIIa, but not FcγRIIIb caused shedding of L-selectin 
expression [88] (Figure 6). Consequently, it was proposed that binding of 
antibodies to FcγRIIIb could induce a proadhesive phenotype of neutrophils [88]. 
More recently, new evidence supporting this idea was found. When each receptor 
was selectively activated with specific monoclonal antibodies, FcγRIIIb but not 
FcγRIIa, was able to activate β1 integrins [77] (Figure 7). This activation resulted 
from an increase in binding affinity to fibronectin [77]. Thus, after neutrophils 
leave the circulation, engagement of FcγRIIIb could lead to activation β1 inte-
grins, allowing the cells to adhere to extracellular matrix proteins and migrate 
into tissues [89] (Figure 1). In contrast, for antibody-mediated phagocytosis 
[17], FcγRIIa was the main Fcγ receptor mediating this response, while FcγRIIIb 
contribution to phagocytosis was minimal [86]. Therefore, at least in human 
neutrophils, each Fcγ receptor initiates particular cell functions. FcγRIIa induces 
phagocytosis (Figure 6), while FcγRIIIb promotes an adhesive phenotype via 
activation of β1 integrins (Figure 7).
In addition, it was also reported that FcγRIIIb signals to the neutrophil nucleus 
more efficiently than FcγRIIa. FcγRIIIb, but not FcγRIIa, induced a large increase 
Figure 6. 
Neutrophil functions activated by FcγRIIa. In human neutrophils, FcγRIIa signaling induces L-selectin shedding 
from the cell membrane, and also activates efficient phagocytosis. The oval represents IgG-opsonized bacteria.
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in phosphorylated ERK in the nucleus, and also efficient phosphorylation of the 
nuclear factor Elk-1 [84] (Figure 7). Interestingly, FcγRIIa also induced phosphory-
lation of ERK in the cytosol [84, 90], but this active ERK seems to function mainly 
in enhancing phagocytosis and not in nuclear signaling [91] (Figure 4).
A recently discovered antimicrobial function of neutrophils is the formation of 
neutrophil extracellular traps (NETs) [92, 93]. NETs are induced by several patho-
gens, including virus, bacteria, fungi, and parasites [94]. Also, pro-inflammatory 
stimuli such as IL-8, TNF-α, and phorbol-12-myristate-13-acetate (PMA) are 
efficient inducers of NETs [95]. Because, antigen-antibody complexes are also 
capable of inducing NET formation [96]; it was clear that FcγRs were involved in 
NET formation. Recently, it was found that FcγRIIIb, but not FcγRIIa, is the recep-
tor responsible for NET formation [78–80] (Figure 8).
Together, all these reports strongly reinforce the modern view that each FcγR 
induces a particular signaling pathway that activates a single cellular function. 
Elucidating the conditions that engage a single type of FcγR to activate a particular 
cellular response would be very helpful in the future for controlling some of cellular 
Figure 7. 
Neutrophil functions activated by FcγRIIIb. Cross-linking of the human FcγRIIIb stimulates activation of β1 
integrins promoting in this way a proadhesive neutrophil phenotype. FcγRIIIb also induces activation of the 
nuclear factor Elk-1 and formation of neutrophil extracellular traps (NETs).
Figure 8. 
Neutrophil FcγRIIIb, but not FcγRIIa, induces neutrophil extracellular traps (NETs) formation. Human 
neutrophils were stimulated by cross-linking FcγRIIa with the specific monoclonal antibody IV.3, or by cross-
linking FcγRIIIb with the specific monoclonal antibody 3G8. After 4 hours, neutrophils were fixed and stained 
for DNA.
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functions in clinical settings. For example, in intense infections, it may be impor-
tant to activate phagocytosis. Because IgG2 binds better to FcγRIIa than to FcγRIIIb 
[33, 35], it is likely that IgG2 antibodies would activate phagocytosis by neutrophils 
much better than other IgG subclass antibodies. In consequence, promoting IgG2 
antibodies against certain pathogens would result in better phagocytosis against 
them.
7. Conclusion
Fcγ receptors expressed in different immune cells are capable of activating dif-
ferent cellular responses important not only for controlling microbial infections but 
also for regulating immunity [71, 97]. Different subclasses of IgG antibodies bind 
the various Fcγ receptors with different affinities [33, 35] and can activate various 
cellular functions of great importance for host defense and for immune regulation. 
In the human neutrophil, it is clear that a specific Fcγ receptor activates particular 
cellular responses. FcγRIIa induces efficient phagocytosis [86], while FcγRIIIb sig-
nals to the nucleus for nuclear factor activation [84] and for NETs formation [78]. 
Therefore, in principle, a particular cell response could be induced or inhibited 
by engaging or blocking the corresponding FcγR. Information similar to the one 
described for neutrophil Fcγ receptors on other immune cells, such as monocytes or 
dendritic cells, is not available. Future research is needed in this area.
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